Up next

Autoplay

Decitabine vs hydroxyurea for advanced proliferative CMML

0 Views • 08/19/25
Share
Side Effects
Side Effects
Subscribers
0

Raphael Itzykson, MD, PhD, Saint-Louis Hospital AP-HP, Paris, France, outlines the results of the Phase III Dacota trial (EudraCT 2014-000200-10), investigating decitabine versus hydroxyurea for patients with advanced proliferative chronic myelomonocytic leukemia (CMML). The study found that decitabine did not provide an overall or event-free survival advantage over hydroxyurea. Additionally, Prof. Itzykson highlights that it is feasible to conduct randomized clinical trials in advanced proliferative CMML, which remains an unmet medical need This interview took place during the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition, 2020.

Show more
0 Comments sort Sort By

Up next

Autoplay